Evidence map›Paper›PMID 40002872›Full record

ArticleBiomedicines2025

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia.

Hanin Aljohani, Doaa Anbarserry, Mahmoud Mosli, Amani Ujaimi, Duaa Bakhshwin, Ramu Elango, Sameer Alharthi

Abstract read
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Diagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanin AljohaniDepartment of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia.
Doaa AnbarserryDepartment of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia.
Mahmoud MosliDepartment of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia.ORCID 0000-0002-6975-1297
Amani UjaimiPrincess Al-Jawahara Cernter of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah 22252, Saudi Arabia.
Duaa BakhshwinDepartment of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia.ORCID 0000-0003-2371-9846
Ramu ElangoPrincess Al-Jawahara Cernter of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah 22252, Saudi Arabia.ORCID 0000-0003-4264-2135
Sameer AlharthiDepartment of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah 22252, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Crohn’s diseasedrug responsegenetic biomarkersrare variantsulcerative colitisvedolizumabwhole-exome sequencing

Identifiers

PMID40002872
PMCPMC11852680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.